Swee Y. Sharp

5.3k citations

45 papers · 2.8k indexed · h-index 25

Toxicology top 1%
- Bioactive Compounds and Antitumor Agents 4
Molecular Biology top 5%
- Heat shock proteins research 29
- ATP Synthase and ATPases Research 12
- Protein Structure and Dynamics 4
Oncology top 5%
- Metal complexes synthesis and properties 4
Computational Theory and Mathematics top 1%
- Computational Drug Discovery Methods 8
Physical and Theoretical Chemistry top 5%
Cell Biology
- Endoplasmic Reticulum Stress and Disease 5
Materials Chemistry
- Enzyme Structure and Function 4

Co-authors: Paul Workman Lloyd R. Kèlland Paul Rogers LR Kelland Philip Beale Timothy G. Myers Steve Hobbs Florence I. Raynaud
Cited by: Toxicology Molecular Biology Oncology
Journals: Cancer Research (8 papers)European Journal of Cancer (3 papers)Molecular Cancer Therapeutics (2 papers)
Partner nations: United Kingdom France Portugal

In The Last Decade

Swee Y. Sharp

45 papers receiving 2.8k citations

Peers

Countries citing papers authored by Swee Y. Sharp

Since Specialization

Citations

This map shows the geographic impact of Swee Y. Sharp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Swee Y. Sharp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Swee Y. Sharp more than expected).

Fields of papers citing papers by Swee Y. Sharp

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Swee Y. Sharp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Swee Y. Sharp. The network helps show where Swee Y. Sharp may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Swee Y. Sharp, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Swee Y. Sharp Line = papers co-authored together Swee Y. Sharp links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Solution structure of the Hop TPR2A domain and investigation of target druggability by NMR, biochemical and in silico approaches Scientific Reports ·M. Warsinsky,Lewis R. Vidler,P. J. Simpson,Bissan Al‐Lazikani,Stephen Matthews,Swee Y. Sharp,Laurence H. Pearl,Swen Hoelder,Paul Workman	2020	11
2	Demonstrating In-Cell Target Engagement Using a Pirin Protein Degradation Probe (CCT367766) Journal of Medicinal Chemistry ·N. Chessum,Swee Y. Sharp,John Caldwell,Bhupati B. Mishra,Birgit Wilding,Giampiero Colombano,Ian Collins,Buğra Özer,魏晓芳,Martin Rowlands,Mark Stubbs,Rosemary Burke,Craig McAndrew,Paul A. Clarke,Paul Workman,Matthew D. Cheeseman,Keith Jones	2017	74
3	Co-Crystalization and In Vitro Biological Characterization of 5-Aryl-4-(5-Substituted-2-4-Dihydroxyphenyl)-1,2,3-Thiadiazole Hsp90 Inhibitors PLoS ONE ·Swee Y. Sharp,S. Mark Roe,Egidijus Kazlauskas,Inga Čikotienė,Paul Workman,Daumantas Matulis,Chrisostomos Prodromou	2012	18
4	Mechanistic Evaluation of the Novel HSP90 Inhibitor NVP-AUY922 in Adult and Pediatric Glioblastoma Molecular Cancer Therapeutics ·Nathalie Gaspar,Swee Y. Sharp,Suzanne A. Eccles,Sharon Gowan,Sergey Popov,Chris Jones,Andrew D.J. Pearson,Gilles Vassal,Paul Workman	2010	62
5	The Association of CCND1 Overexpression and Cisplatin Resistance in Testicular Germ Cell Tumors and Other Cancers American Journal Of Pathology ·Elodie Noël,Marc Yeste‐Velasco,Xueying Mao,Erik Wengström,Sakunthala C. Kudahetti,Ningfeng Fiona Li,Swee Y. Sharp,Tracy Chaplin,Liyan Xue,Alan McIntyre,Ling Shan,Thomas Powles,R.T.D. Oliver,Bryan D. Young,Janet Shipley,Daniel M. Berney,Simon P. Joel,Yong‐Jie Lu	2010	86
6	Inhibition of Hsp90 with Resorcylic Acid Macrolactones: Synthesis and Binding Studies Chemistry - A European Journal ·James E. H. Day,Swee Y. Sharp,Martin Rowlands,Wynne Aherne,William Lewis,S. Mark Roe,Chrisostomos Prodromou,Laurence H. Pearl,Paul Workman,Christopher J. Moody	2010	21
7	EGFRvIII Deletion Mutations in Pediatric High-Grade Glioma and Response to Targeted Therapy in Pediatric Glioma Cell Lines Clinical Cancer Research ·Dorine A. Bax,Nathalie Gaspar,Suzanne E. Little,Lynley V. Marshall,Lara Perryman,Marie Regairaz,Marta Viana‐Pereira,Raisa Vuononvirta,Swee Y. Sharp,Jorge S. Reis‐Filho,João N. Stávale,Safa Al‐Sarraj,Rui Manuel Reis,Gilles Vassal,Andrew D.J. Pearson,Darren Hargrave,David W. Ellison,Paul Workman,Chris Jones	2009	71
8	Acquired Resistance to 17-Allylamino-17-Demethoxygeldanamycin (17-AAG, Tanespimycin) in Glioblastoma Cells Cancer Research ·Nathalie Gaspar,Swee Y. Sharp,Simon Pacey,Chris Jones,Michael I. Walton,Gilles Vassal,Suzanne A. Eccles,Andrew D.J. Pearson,Paul Workman	2009	92
9	Silencing of HSP90 Cochaperone AHA1 Expression Decreases Client Protein Activation and Increases Cellular Sensitivity to the HSP90 Inhibitor 17-Allylamino-17-Demethoxygeldanamycin Cancer Research ·E A Ríos-Zavala,Swee Y. Sharp,Steve Hobbs,Paul Workman	2008	104
10	Acquired resistance to HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) in adult and pediatric glioblastoma cell lines Cancer Research ·Nathalie Gaspar,Swee Y. Sharp,Simon Pacey,Chris Jones,Mike Walton,Gilles Vassal,Andrew D.J. Pearson,Paul Workman	2008	1
11	An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models Cancer Chemotherapy and Pharmacology ·Udai Banerji,L.A. Wori,Swee Y. Sharp,Melanie Valenti,Yasmin J. Asad,Ruth Ruddle,Florence I. Raynaud,Michael I. Walton,Suzanne A. Eccles,Ian Judson,Ann L. Jackman,Paul Workman	2008	30
12	Synthetic ansamycins prepared by a ring-expanding Claisen rearrangement. Synthesis and biological evaluation of ring and conformational analogues of the Hsp90 molecular chaperone inhibitor geldanamycin Organic & Biomolecular Chemistry ·Christopher S. P. McErlean,徐正文,Christopher J. Davis,A. M.,Swee Y. Sharp,Kathy Boxall,Alexandra M. Z. Slawin,Paul Workman,Christopher J. Moody	2007	16
13	NVP-AUY922 / VER-52296: A novel 3,4 diarylisoxazole Hsp90 chaperone inhibitor discovered via structure-based drug design Molecular Cancer Therapeutics ·Paul A. Brough,Andrew J. Massey,Martin J. Drysdale,Xavier Barril,Brian Dymock,Suzanne A. Eccles,Harry Finch,Rod Hubbard,Edward McDonald,Florence I. Raynaud,Swee Y. Sharp,Alan Surgenor,Mike Wood,Paul Workman,Lisa Wright	2007	1
14	Solid-Phase Immunoassays in Mechanism-Based Drug Discovery: Their Application in the Development of Inhibitors of the Molecular Chaperone Heat-Shock Protein 90 Assay and Drug Development Technologies ·Anthea Hardcastle,Kathy Boxall,E Conde,P J Tomlin,Swee Y. Sharp,Paul A. Clarke,Paul Workman,Wynne Aherne	2005	8
15	Mechanism of action of a novel series of inhibitors of the Hsp90 molecular chaperone Cancer Research ·Swee Y. Sharp,Alison Maloney,Paul A. Clarke,Wynne Aherne,Suzanne A. Eccles,Kathy Boxall,Martin Rowlands,Florence I. Raynaud,Bernard Nutley,Nicola F. Smith,Angela Hayes,Anthea Hardcastle,Laurence H. Pearl,律子今村,郭文驥,Maria Amaral,Thomas P. Matthews,Yvonne Eckersley,Martin J. Drysdale,Paul Workman	2004	1
16	Induction of Hsp70 and depletion of the client protein c-Raf-1 measured by ELISA following cellular exposure to the novel Hsp90 ATPase inhibitor, CCT018159 Wynne Aherne,Anthea Hardcastle,K. Boxall,E Conde,P J Tomlin,Swee Y. Sharp,Alison Maloney,Paul Workman	2003	2
17	Mechanisms of drug resistance to the platinum complex ZD0473 in ovarian cancer cell lines European Journal of Cancer ·K. Ohshita,Philip Beale,Frances Boxall,Swee Y. Sharp,Lloyd R. Kèlland	2000	61
18	BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma British Journal of Cancer ·Philip Beale,Paul Rogers,Frances Boxall,Swee Y. Sharp,LR Kelland	2000	93
19	DT-Diaphorase Expression and Tumor Cell Sensitivity to 17-Allylamino,17-demethoxygeldanamycin, an Inhibitor of Heat Shock Protein 90 JNCI Journal of the National Cancer Institute ·LR Kelland,Swee Y. Sharp,Paul Rogers,Timothy G. Myers,Paul Workman	1999	280
20	In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473 British Journal of Cancer ·K. Ohshita,Swee Y. Sharp,Barry A. Murrer,Michael J. Abrams,Lloyd R. Kèlland	1998	172

About Swee Y. Sharp

Swee Y. Sharp is a scholar working on Toxicology, Molecular Biology and Computational Theory and Mathematics, having authored 45 papers that have together received 2.8k indexed citations. Recurring topics across this work include Heat shock proteins research (29 papers), ATP Synthase and ATPases Research (12 papers), Computational Drug Discovery Methods (8 papers), Endoplasmic Reticulum Stress and Disease (5 papers), Bioactive Compounds and Antitumor Agents (4 papers), Protein Structure and Dynamics (4 papers), Metal complexes synthesis and properties (4 papers) and Enzyme Structure and Function (4 papers). The work is most often cited by research in Toxicology (124 citations), Molecular Biology (2.0k citations) and Oncology (750 citations). Swee Y. Sharp has collaborated with scholars based in United Kingdom, France and Portugal. Frequent co-authors include Paul Workman, Lloyd R. Kèlland, Paul Rogers, LR Kelland, Philip Beale, Timothy G. Myers, Steve Hobbs, Florence I. Raynaud, Michael J. Abrams and Barry A. Murrer. Their work appears in journals such as Cancer Research, European Journal of Cancer, Molecular Cancer Therapeutics, British Journal of Cancer and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact